Combination immunotherapy for advanced colorectal cancer after multiple treatments
Treatments studied
Part of Cancer clinical trials.
This trial tests a mix of three drugs (sintilimab, bevacizumab, and decitabine) for people with advanced colorectal cancer that has a stable or low amount of genetic change. It’s for those whose cancer has grown after at least two prior treatments, and who have not had immunotherapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that is MSS or pMMR type (not MSI-H).
- Your cancer has gotten worse after at least two standard treatments, including drugs like irinotecan, oxaliplatin, or fluorouracil.
- You are able to take care of yourself (ECOG score 0 or 1).
- You have not received immunotherapy drugs like PD-1 or PD-L1 inhibitors before.
- You do not have active autoimmune disease that needs strong immune-suppressing medicine.
- You are willing to provide a tumor sample (either from a past biopsy or a new one).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus chemotherapy for people with a specific type of colorectal cancer that hasn't spread to the liver. It may be an option if your cancer is mismatch repair stable (MSS or pMMR) and has progressed after initial treatment.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
This trial tests a combination of targeted radiation therapy, an immune-boosting drug, and two chemotherapy drugs for colorectal cancer that has spread or come back after two rounds of prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.